Development of new targeted drugs for pulmonary arterial hypertension / 国际药学研究杂志

ABSTRACT

Pulmonary arterial hypertension(PAH)is a rare disease characterized by progressive elevation of pulmonary vascular resistance that leads to right heart failure and even death. The prognosis of PAH is poor. Before 1990, the era of conventional therapy, patients with PAH were mainly treated with general supportive therapy and calcium channel blockers (CCB). Since 1990, with the coming of the era of new drugs, the advent of compounds targeted at three pathways (prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors) has improved the clinical symptoms, exercise capacity, and even survival of patients with PAH. In recent years, there have been great research advances in the pathogenesis of PAH, and now more novel drugs are being investigated in clinical trials, which will lead to a burst in the treatment of PAH.